MCCQE Part I medicine: cardiology & respirology questions

ST elevation in the inferior leads (II, III, aVF) with reciprocal ST depression in the high lateral leads (I, aVL) is characteristic of an acute inferior wall STEMI, typically from occlusion of the right coronary artery or, less commonly, a dominant left circumflex artery. Reciprocal changes are ST depressions in leads electrically opposite to the infarct territory and support an ischemic rather than a diffuse inflammatory process. Pericarditis classically causes diffuse concave ST elevation without reciprocal depression and is often accompanied by PR depression. Recognizing the inferior pattern should prompt right-sided ECG leads to assess for right ventricular involvement.

• B. Anterior STEMI would show ST elevation in V1-V4, not II, III, and aVF.
• C. Posterior STEMI shows ST depression in V1-V3 with tall R waves, not the lead pattern described.
• D. Lateral STEMI would show ST elevation in I, aVL, V5-V6, which are the reciprocal leads here, not the affected ones.
• E. Pericarditis causes diffuse ST elevation without reciprocal depression, unlike the localized pattern here.

For patients with STEMI presenting to a PCI-capable centre, primary percutaneous coronary intervention is the preferred reperfusion strategy, with a target door-to-balloon time of 90 minutes or less. Primary PCI achieves higher rates of infarct-related artery patency and lower rates of recurrent ischemia, stroke, and death compared with fibrinolysis when performed promptly by an experienced team. Fibrinolysis is reserved for situations where timely PCI is not available. Echocardiography and extended observation would only delay definitive reperfusion therapy and are not appropriate initial steps in a STEMI with an available catheterization lab.

• A. Echocardiography is not required before reperfusion and would only delay time-critical treatment.
• C. Fibrinolysis is inferior to primary PCI when a catheterization lab is immediately available within guideline time targets.
• D. Observation alone without reperfusion therapy would allow ongoing myocardial necrosis.
• E. Beta-blockade does not substitute for emergent reperfusion in STEMI.

When anticipated time from first medical contact to primary PCI exceeds 120 minutes, fibrinolytic therapy should be administered promptly (ideally within 30 minutes of arrival) rather than delaying reperfusion for transfer. After fibrinolysis, the patient should still be transferred to a PCI-capable centre for rescue PCI if reperfusion fails, or for routine angiography within 24 hours if fibrinolysis is successful, a pharmacoinvasive strategy. Waiting over 2 hours for primary PCI in this scenario would result in excessive myocardial loss. Anticoagulation alone, antiplatelet therapy without reperfusion, and waiting for troponin confirmation all inappropriately delay definitive treatment of an ECG-confirmed STEMI.

• A. STEMI diagnosis is made by ECG, and treatment should not be delayed pending troponin results.
• B. Antiplatelet therapy alone without reperfusion and discharge is inappropriate management of an acute STEMI.
• C. Transferring without fibrinolysis would expose the patient to over 2 hours of ongoing infarction, exceeding the acceptable delay threshold.
• D. Anticoagulation alone does not achieve reperfusion of the occluded artery.

Standard initial medical therapy for NSTEMI includes dual antiplatelet therapy with acetylsalicylic acid plus a P2Y12 inhibitor such as ticagrelor, a parenteral anticoagulant such as fondaparinux, enoxaparin, or unfractionated heparin, and a high-intensity statin, all started promptly regardless of whether angiography is immediate or delayed. Ticagrelor is generally preferred over clopidogrel in ACS due to superior reduction in cardiovascular death demonstrated in major trials, unless contraindicated. Anticoagulation should not be withheld since it reduces ischemic events while awaiting catheterization. Statin therapy should be initiated immediately at high intensity rather than deferred, as benefit is independent of baseline LDL level, and warfarin and prasugrel are not first-line choices in this context (prasugrel is avoided before coronary anatomy is known due to bleeding risk if CABG is needed).

• A. Unfractionated heparin for ACS is given intravenously with weight-based dosing, not subcutaneously.
• B. Warfarin has no role in acute ACS management, and statin intensity should be high regardless of baseline LDL.
• C. Anticoagulation should be started promptly in NSTEMI, not withheld until after angiography.
• D. Prasugrel is avoided prior to knowing coronary anatomy due to bleeding risk if CABG is required, and statin therapy should not be delayed.

This patient has an inferior STEMI with clinical signs of right ventricular infarction: elevated jugular venous pressure with clear lungs and hypotension. A infarcted right ventricle becomes stiff and poorly contractile, making cardiac output critically dependent on adequate right ventricular preload to maintain flow across the pulmonary circuit. Nitroglycerin causes venodilation and reduces preload, which can precipitate severe hypotension or cardiogenic shock in this setting, so nitrates and other preload-reducing agents such as diuretics should be avoided in suspected right ventricular infarction. Management instead involves careful intravenous fluid administration to maintain right ventricular filling pressures. Right-sided ECG leads (V4R) showing ST elevation help confirm the diagnosis.

• B. Nitroglycerin does not characteristically cause vagally mediated bradycardia as its primary hypotensive mechanism; the clear lungs and elevated JVP point to preload dependence instead.
• C. Coronary steal is not the mechanism of nitrate-induced hypotension in right ventricular infarction.
• D. The presentation lacks a new systolic murmur or pulmonary edema expected with acute mitral regurgitation.
• E. Nitrates cause vasodilation, not vasospasm, and this does not explain the hemodynamic collapse described.

Papillary muscle rupture is a mechanical complication of myocardial infarction, classically occurring 2 to 7 days after an inferior MI due to posteromedial papillary muscle involvement from right coronary artery occlusion. It presents with sudden-onset acute severe mitral regurgitation, causing a new holosystolic murmur at the apex radiating to the axilla, along with acute pulmonary edema and cardiogenic shock due to the heart's inability to accommodate the sudden volume overload. Ventricular septal rupture also occurs in this time window but produces a harsh holosystolic murmur at the lower left sternal border, often with a palpable thrill, rather than at the apex. Free wall rupture classically presents with sudden hemodynamic collapse and tamponade physiology without a new murmur.

• B. Free wall rupture typically presents with tamponade and electromechanical dissociation rather than a new murmur.
• C. Ventricular septal rupture produces a murmur at the lower left sternal border, not at the apex radiating to the axilla.
• D. Ventricular aneurysm develops later and presents with heart failure or arrhythmia, not an acute new murmur with pulmonary edema.
• E. A new murmur radiating to the axilla is not explained by recurrent infarction alone.

Diabetes mellitus is a statin-indicated condition under Canadian Cardiovascular Society dyslipidemia guidelines regardless of calculated Framingham Risk Score, particularly in patients 40 years of age or older or with disease duration beyond 15 years, or with additional risk factors such as age over 55 or microvascular complications. Statin therapy is recommended to reduce cardiovascular risk even when LDL cholesterol is not markedly elevated, because the benefit is independent of baseline LDL in these high-risk groups. Calculating a Framingham score is unnecessary once a statin-indicated condition such as diabetes is identified.

• A. Fibrates are not first-line therapy for cardiovascular risk reduction in diabetes; statins are indicated.
• B. Framingham Risk Score calculation is unnecessary because diabetes is already a statin-indicated condition independent of calculated risk.
• C. LDL cholesterol level does not override the statin indication conferred by diabetes in this age group.
• D. Deferring further testing delays indicated therapy; the statin indication is already established by the diagnosis of diabetes.

Canadian medical fitness-to-drive guidelines (CMA Driver's Guide) require a minimum driving restriction for commercial drivers after myocardial infarction, generally at least 1 month, with resumption contingent on satisfactory functional status and no high-risk features. Physicians in most Canadian provinces and territories have a legal obligation to report medical conditions that may impair safe driving to the provincial licensing authority, which overrides patient confidentiality for public safety reasons. Commercial drivers face stricter restrictions than private drivers because of the higher risk posed to the public, but a single uncomplicated MI with preserved ejection fraction does not permanently bar licensure.

• A. 48 hours is far too short a restriction period for a commercial driver after myocardial infarction.
• B. A single MI with preserved ejection fraction and no complications does not result in permanent disqualification from commercial driving.
• D. Physicians have a mandatory legal obligation in most Canadian jurisdictions to report conditions affecting fitness to drive to the licensing authority.
• E. Immediate return to commercial driving after MI is unsafe and violates mandated restriction periods for commercial licenses.

A markedly elevated NT-proBNP in the setting of dyspnea, elevated jugular venous pressure, bibasilar crackles, and peripheral edema strongly supports a diagnosis of heart failure, and an ejection fraction of 30% confirms heart failure with reduced ejection fraction. Natriuretic peptides are released in response to myocardial wall stress and are markedly elevated in decompensated heart failure, with levels this high making alternative diagnoses far less likely. Pneumonia, COPD exacerbation, and pulmonary embolism do not typically cause such pronounced natriuretic peptide elevation or this constellation of volume overload findings, and nephrotic syndrome causes edema without this degree of natriuretic peptide rise or reduced ejection fraction.

• B. COPD exacerbation does not typically cause such pronounced natriuretic peptide elevation or depressed ejection fraction.
• C. Pulmonary embolism would not typically cause an ejection fraction of 30% and such a markedly elevated NT-proBNP with this presentation.
• D. Community-acquired pneumonia does not explain elevated jugular venous pressure, bilateral edema, and a markedly reduced ejection fraction.
• E. Nephrotic syndrome causes edema through hypoalbuminemia without this degree of NT-proBNP elevation or reduced ejection fraction.

Current heart failure guidelines recommend early initiation of all four pillars of guideline-directed medical therapy (ARNI or ACE inhibitor, beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor) as tolerated, with beta-blockers started as soon as the patient is euvolemic and hemodynamically stable. Beta-blockers such as bisoprolol, carvedilol, or metoprolol succinate reduce mortality and hospitalization in HFrEF by blunting the deleterious effects of chronic sympathetic activation. There is no requirement to wait for maximal uptitration of one class before starting another; rapid sequential initiation is now preferred over the traditional stepwise approach. This patient has no contraindications such as bradycardia or decompensated shock, so a beta-blocker is the appropriate next agent.

• A. Calcium channel blockers (non-dihydropyridine) are not part of HFrEF therapy and can worsen outcomes due to negative inotropic effects.
• C. Centrally acting alpha-2 agonists have no role in HFrEF management.
• D. Alpha-1 blockers are not part of standard HFrEF therapy and have been associated with worse heart failure outcomes.
• E. Loop diuretics improve congestive symptoms but do not alter mortality and are not one of the four pillars of GDMT.

This patient has signs and symptoms of heart failure (dyspnea, elevated JVP, crackles, edema) with an elevated natriuretic peptide and echocardiographic evidence of diastolic dysfunction (impaired relaxation, elevated filling pressures, left atrial enlargement) despite a preserved ejection fraction of 58%. This combination defines heart failure with preserved ejection fraction, which is common in older patients with hypertension and diabetes, risk factors that promote left ventricular hypertrophy and reduced compliance. Unlike HFrEF, the primary abnormality is impaired ventricular relaxation and filling rather than impaired systolic contraction. Management differs from HFrEF, focusing on volume control, blood pressure management, and SGLT2 inhibitors rather than the full neurohormonal blockade pillar regimen.

• A. HFrEF requires an ejection fraction below 40%, which is inconsistent with this patient's EF of 58%.
• B. COPD would present with obstructive spirometry findings, not elevated JVP, crackles, and diastolic dysfunction on echocardiography.
• D. Constrictive pericarditis typically shows pericardial thickening or calcification and a characteristic septal bounce, not the diastolic Doppler pattern described here.
• E. Pulmonary embolism presents acutely with pleuritic pain, hypoxia, and tachycardia, not a 3-month progressive course with echocardiographic diastolic dysfunction.

This patient has acute decompensated heart failure with pulmonary edema, evidenced by severe dyspnea, hypoxia, elevated jugular venous pressure, and bilateral crackles. After securing oxygenation, intravenous loop diuretics such as furosemide are the cornerstone of initial therapy, promoting rapid diuresis and natriuresis to relieve pulmonary congestion. Intravenous nitrates may be added if blood pressure remains adequate to further reduce preload and afterload, but diuresis is the priority intervention in a volume-overloaded patient. Beta-blockers and ARNIs are part of chronic outpatient GDMT and should not be initiated or increased during acute decompensation with evidence of congestion. Inotropes such as dobutamine are reserved for cardiogenic shock with hypoperfusion, which is not present here given the preserved blood pressure.

• A. Dobutamine is reserved for cardiogenic shock with hypotension and hypoperfusion, not present in this normotensive patient.
• B. Sacubitril-valsartan is an oral chronic therapy, not appropriate for acute decompensation and may cause hypotension.
• C. A fluid bolus would worsen pulmonary congestion in this volume-overloaded patient.
• D. Beta-blockers should not be started or escalated during acute decompensation; they are appropriate once the patient is euvolemic and stable.

ACE inhibitor–induced angioedema results from bradykinin accumulation due to inhibition of ACE-mediated bradykinin degradation and is not IgE-mediated, explaining the absence of urticaria or pruritus. Once angioedema occurs, ACE inhibitors must be permanently discontinued and should not be rechallenged or substituted with another ACE inhibitor. Angiotensin receptor blockers such as candesartan act on the renin-angiotensin system without significantly affecting bradykinin metabolism, carrying a much lower (though not zero) risk of angioedema, and are recommended as the preferred alternative in guidelines for HFrEF patients with ACE inhibitor intolerance. Direct renin inhibitors like aliskiren also carry bradykinin-related angioedema risk and are not recommended as a substitute.

• A. Aliskiren, a direct renin inhibitor, also carries a risk of angioedema and is not a recommended substitute.
• C. Hydrochlorothiazide does not provide the mortality benefit of renin-angiotensin system blockade required in HFrEF.
• D. Rechallenging with a lower dose of the same ACE inhibitor risks recurrent, potentially life-threatening angioedema.
• E. Switching to another ACE inhibitor carries the same class-related risk of bradykinin-mediated angioedema.

This presentation, exertional dyspnea, near-syncope, a harsh crescendo-decrescendo systolic murmur radiating to the carotids, delayed carotid upstroke (pulsus parvus et tardus), and a soft or absent second heart sound, is classic for severe aortic stenosis. Transthoracic echocardiography is the investigation of choice because it confirms the diagnosis, quantifies severity (aortic valve area, mean gradient, peak velocity), assesses left ventricular function, and guides decisions about valve replacement. Exercise stress testing is contraindicated in symptomatic severe aortic stenosis due to the risk of hemodynamic collapse. Coronary angiography is often performed before valve intervention to assess for concurrent coronary disease but does not establish the valvular diagnosis itself.

• B. Cardiac MRI is not first-line for valvular assessment and is reserved for specific indications such as aortic root or myocardial tissue characterization.
• C. Exercise stress testing is contraindicated in symptomatic patients with suspected severe aortic stenosis due to risk of syncope or sudden death.
• D. Coronary angiography may be needed before intervention to evaluate coronary anatomy but does not quantify valve severity.
• E. Chest radiography may show cardiomegaly or valve calcification but cannot quantify the severity of stenosis.

A holosystolic murmur at the apex radiating to the axilla that increases with handgrip (increased afterload augments regurgitant flow) and does not change with Valsalva is characteristic of mitral regurgitation. Aortic stenosis produces a crescendo-decrescendo murmur best heard at the right upper sternal border radiating to the carotids, with delayed/diminished carotid upstrokes, and it decreases with handgrip because of reduced gradient across the valve. Normal carotid upstrokes argue against significant aortic stenosis.

• A. Aortic stenosis produces a crescendo-decrescendo systolic murmur radiating to the carotids with reduced upstrokes, not a holosystolic apical murmur.
• B. Mitral valve prolapse typically produces a mid-systolic click followed by a late systolic murmur, not holosystolic.
• C. HOCM murmur increases with Valsalva and decreases with handgrip, the opposite pattern described here.
• D. Aortic regurgitation causes an early diastolic decrescendo murmur, not a systolic one.

Symptomatic severe aortic stenosis is an indication for valve replacement regardless of ejection fraction, since untreated severe symptomatic AS carries high mortality. In elderly, frail patients with intermediate-to-high surgical risk and favorable vascular anatomy, transcatheter aortic valve implantation (TAVI) is preferred over surgical AVR because it offers comparable or superior outcomes with lower periprocedural morbidity. A heart team evaluation, as described, is required to confirm candidacy and anatomic suitability before proceeding. Watchful waiting or medical therapy alone is inappropriate because they do not alter the natural history of severe symptomatic AS.

• A. Medical therapy does not change the natural history of severe symptomatic aortic stenosis and delays definitive treatment.
• B. Surgical AVR carries higher perioperative risk in this frail, elevated-STS-risk patient when TAVI is anatomically feasible.
• C. Watchful waiting is inappropriate once symptoms develop, as the prognosis worsens rapidly without valve replacement.
• E. Balloon valvuloplasty is a temporizing measure with high restenosis rates, not definitive therapy in a TAVI/AVR candidate.

The modified Duke criteria classify a case as definite infective endocarditis when two major criteria are met. Here, both major criteria are satisfied: typical microorganism (Staphylococcus aureus) isolated from three separate blood cultures, and echocardiographic evidence of a vegetation. Fever and intravenous drug use are minor criteria but are not needed once two major criteria are present. Transesophageal echocardiography is more sensitive but is not required for classification when transthoracic imaging already demonstrates a definitive vegetation.

• B. Classification can be made on the data already presented; TEE is not mandatory once TTE shows a clear vegetation plus positive cultures.
• C. Culture-negative endocarditis applies when cultures fail to grow an organism, which is not the case here.
• D. Rejected endocarditis requires resolution of the syndrome with little or no antibiotic therapy or an alternate firm diagnosis, neither of which applies here.
• E. Possible endocarditis applies when one major plus one minor, or three minor criteria, are met; this case meets two major criteria.

A childhood history suggestive of untreated rheumatic fever (migratory polyarthritis, fever, rash), combined with a loud S1 and low-pitched diastolic rumble at the apex, is classic for mitral stenosis from rheumatic heart disease. Chronic mitral stenosis causes left atrial enlargement and stretch, predisposing to atrial fibrillation, which explains the irregular rhythm and absent P waves. Rheumatic heart disease remains the leading cause of mitral stenosis worldwide, particularly in populations with limited access to childhood antibiotic treatment of streptococcal pharyngitis. The clinical picture here is not consistent with regurgitant or right-sided valve lesions.

• A. Carcinoid-related tricuspid stenosis would present with flushing and diarrhea, and findings would localize to the right side, not the apex.
• B. Aortic stenosis produces a systolic murmur at the right upper sternal border, not an apical diastolic rumble.
• C. Mitral regurgitation produces a holosystolic murmur, not a diastolic rumble, and does not fit the rheumatic fever history as well as stenosis.
• E. Atrial myxoma can mimic mitral stenosis but would not explain the childhood rheumatic fever history, which strongly points to a rheumatic etiology.

The CHADS-65 algorithm used in Canadian guidelines indicates that any patient with atrial fibrillation aged 65 years or older should receive oral anticoagulation regardless of additional risk factors, because age alone confers sufficient stroke risk. This patient is 71 years old, so he meets criteria for anticoagulation independent of his CHADS2 score. A direct oral anticoagulant is preferred over warfarin as first-line therapy in non-valvular atrial fibrillation because of comparable or superior efficacy, lower bleeding risk, and no need for routine monitoring. Antiplatelet therapy alone is not recommended for stroke prevention in atrial fibrillation.

• A. Antiplatelet monotherapy is inferior to oral anticoagulation for stroke prevention in atrial fibrillation and is not recommended.
• B. Warfarin is an acceptable alternative but DOACs are preferred first-line in non-valvular AF due to better safety profile and no monitoring requirement.
• D. Dual antiplatelet therapy is not an evidence-based strategy for stroke prevention in atrial fibrillation.
• E. Age 65 or older with atrial fibrillation mandates anticoagulation under CHADS-65; reassessment without treatment is inappropriate.

In non-valvular atrial fibrillation without mechanical heart valves or moderate-to-severe mitral stenosis, direct oral anticoagulants such as apixaban are recommended first-line over warfarin because of similar or better efficacy in stroke prevention, lower rates of intracranial hemorrhage, and no requirement for routine coagulation monitoring. Warfarin remains necessary specifically for valvular atrial fibrillation, including mechanical prosthetic valves or rheumatic mitral stenosis, where DOACs have shown inferior outcomes. Parenteral anticoagulants and antiplatelet regimens are not appropriate for long-term stroke prevention in atrial fibrillation.

• A. Dual antiplatelet therapy is inferior to anticoagulation for stroke prevention in atrial fibrillation.
• B. Unfractionated heparin is used for short-term parenteral anticoagulation, not long-term stroke prevention in AF.
• C. Warfarin is reserved for valvular AF (mechanical valves or significant mitral stenosis); DOACs are preferred in non-valvular AF.
• D. Enoxaparin is not indicated for chronic stroke prevention in atrial fibrillation.

This patient has a tachyarrhythmia causing hemodynamic instability, evidenced by hypotension and altered mental status, which is an indication for immediate synchronized cardioversion regardless of the specific rhythm. Pharmacologic measures and vagal maneuvers are appropriate only in stable patients because they take longer to act and may delay definitive treatment of an unstable arrhythmia. Synchronized cardioversion delivers a shock timed to the QRS complex to avoid inducing ventricular fibrillation, which is important in organized rhythms such as this narrow-complex tachycardia. Any delay to pursue medical therapy in an unstable patient risks hemodynamic collapse.

• B. Beta-blockers are too slow-acting and risk worsening hypotension in an unstable patient.
• C. Adenosine may be tried in stable narrow-complex tachycardia but is not appropriate when the patient is hemodynamically unstable requiring immediate cardioversion.
• D. Vagal maneuvers are a reasonable first step only in stable patients, not when there is hypotension and altered mental status.
• E. Amiodarone infusion takes too long to achieve rhythm control and is not first-line in an unstable patient.

This is a hemodynamically stable regular narrow-complex tachycardia (most likely AV nodal re-entrant tachycardia) that has not responded to vagal maneuvers, which is the indication for intravenous adenosine. Adenosine transiently blocks conduction through the AV node by activating A1 receptors, which increases potassium efflux and hyperpolarizes the cell, interrupting the re-entrant circuit. It is given as a rapid bolus followed by a saline flush because of its very short half-life (under 10 seconds). Cardioversion is reserved for unstable patients or when pharmacologic therapy fails.

• A. Beta-blockers are second-line after adenosine for recurrent or adenosine-unresponsive SVT, not the initial agent.
• B. Synchronized cardioversion is reserved for hemodynamically unstable patients, which this patient is not.
• C. Digoxin has a slow onset and is not used for acute termination of SVT in the emergency setting.
• D. Amiodarone is not first-line for acute termination of stable narrow-complex SVT and acts too slowly.

AV dissociation and precordial concordance are highly specific findings for ventricular tachycardia in a wide-complex tachycardia, reflecting a ventricular origin where impulses do not consistently conduct retrogradely to the atria and spread through the ventricle in one uniform direction. A prior myocardial infarction with scar is a major risk factor for re-entrant VT, making this the most likely diagnosis in this clinical context. SVT with aberrancy typically shows a 1:1 relationship between P waves and QRS complexes. When the diagnosis of wide-complex tachycardia is uncertain, it should be treated as VT until proven otherwise.

• B. Sinus tachycardia would show a 1:1 relationship between P waves and QRS complexes, not dissociation.
• C. Antidromic AVRT is rare and typically shows 1:1 atrial-ventricular relationship rather than dissociation.
• D. Atrial fibrillation is irregularly irregular, not a regular wide-complex tachycardia as described here.
• E. SVT with bundle branch block would usually show a consistent 1:1 P-QRS relationship, not AV dissociation.

In patients with diabetes and hypertension, Hypertension Canada recommends an ACE inhibitor or ARB as first-line therapy, particularly because of their renoprotective effects, even in the absence of current albuminuria, since diabetes carries a high lifetime risk of diabetic nephropathy. Ramipril, an ACE inhibitor, reduces intraglomerular pressure and has demonstrated reduction in progression to albuminuria and cardiovascular events in diabetic patients. Thiazide diuretics and calcium channel blockers are acceptable alternatives but are not preferred first-line in diabetes with this profile. Beta-blockers are not first-line for uncomplicated hypertension and can mask hypoglycemia symptoms in diabetic patients, while alpha-blockers are not recommended as first-line therapy for hypertension.

• A. Thiazide diuretics are an acceptable option but ACE inhibitors or ARBs are preferred first-line in patients with diabetes.
• B. Beta-blockers are not recommended as first-line therapy for uncomplicated hypertension and can mask hypoglycemia.
• D. Calcium channel blockers are acceptable alternatives but are not preferred first-line over ACE inhibitors in diabetic patients.
• E. Alpha-blockers are not recommended as first-line monotherapy for hypertension in any patient subgroup.

Resistant hypertension in a young patient with unexplained hypokalemia is a classic trigger for screening for primary hyperaldosteronism, and the plasma aldosterone-to-renin ratio is the recommended initial screening test. Primary hyperaldosteronism causes sodium retention and potassium wasting through excess mineralocorticoid activity at the renal tubule, producing hypertension with hypokalemia often resistant to standard triple therapy. While renal artery stenosis should also be considered in resistant hypertension, the presence of hypokalemia makes hyperaldosteronism the more likely diagnosis to pursue first. Cushing syndrome and thyroid disease are less consistent with this specific biochemical pattern, and sleep apnea testing, while reasonable in resistant hypertension generally, would not address the hypokalemia.

• A. Sleep apnea is a cause of resistant hypertension but does not explain the hypokalemia and is not the best initial test here.
• B. Thyroid dysfunction does not typically produce this pattern of resistant hypertension with hypokalemia.
• C. Renal artery imaging is reasonable in resistant hypertension but the hypokalemia points more specifically toward hyperaldosteronism as the first test.
• D. Cushing syndrome can cause hypertension and hypokalemia but is less common and this presentation lacks other cushingoid features.

This patient has hypertensive emergency (markedly elevated blood pressure with acute target-organ damage, here grade III-IV hypertensive retinopathy). The goal is controlled, gradual reduction of mean arterial pressure by about 20-25% within the first hour using a titratable intravenous agent such as labetalol or nicardipine, with further gradual normalization over the next 24-48 hours. Rapid normalization risks cerebral, coronary, or renal hypoperfusion because autoregulatory thresholds have shifted upward. Oral agents and unmonitored approaches do not allow the fine titration needed in this setting.

• A. Oral amlodipine is not titratable and this target is far too aggressive for the first hours.
• B. Acute target-organ damage requires prompt controlled lowering, not observation alone.
• C. Reducing to normotensive levels this quickly risks ischemic organ injury from relative hypoperfusion.
• E. Hydralazine boluses are poorly titratable and this target normalizes pressure too quickly and too far.

In bilateral renal artery stenosis, glomerular filtration distal to the stenosis depends on angiotensin II-mediated constriction of the efferent arteriole to maintain filtration pressure. ACE inhibitors (and ARBs) block this compensatory mechanism, causing a marked, potentially irreversible drop in GFR and acute kidney injury. This is why renal function and potassium must be checked before and shortly after starting these agents, and why bilateral renal artery stenosis (or stenosis in a solitary kidney) is a contraindication. ACE inhibitors are also contraindicated in pregnancy due to fetopathy, but that is not the mechanism relevant here.

• B. The clinically important effect is loss of efferent, not afferent, arteriolar tone.
• C. ACE inhibitors reduce aldosterone secretion and tend to cause hyperkalemia, not hypokalemia.
• D. This mechanism describes an immune-mediated glomerulonephritis, not the effect of ACE inhibition.
• E. ACE inhibitors cause a hemodynamic, not a direct cytotoxic, effect on the tubules.

The Canadian Task Force on Preventive Health Care recommends one-time ultrasound screening for abdominal aortic aneurysm in men aged 65-80 years who have ever smoked (even remotely), given their substantially higher prevalence of AAA. For men in this age range who have never smoked, routine screening is not recommended because the yield is low and the harms of overdiagnosis and unnecessary intervention outweigh the benefits. Screening recommendations differ for women, who are generally not recommended for routine screening regardless of smoking status.

• B. Ultrasound, not CT, is the recommended and least invasive screening modality when screening is indicated.
• C. Screening, when indicated, is one-time rather than annual, and this patient does not meet screening criteria at all.
• D. Waiting for a palpable mass would miss most aneurysms and defeats the purpose of screening before symptoms develop.
• E. Routine ultrasound screening in a never-smoker of this age is not recommended because expected yield is too low to outweigh harms.

This presentation (tearing chest pain, interarm blood pressure discrepancy, and a new diastolic murmur suggesting aortic regurgitation) is classic for acute aortic dissection. In a hemodynamically stable patient, contrast-enhanced CT angiography of the chest, abdomen, and pelvis is the investigation of choice because it is rapidly available, highly sensitive and specific, and defines the full extent of the dissection to guide management. Transesophageal echocardiography is an alternative when the patient is too unstable to go to the CT scanner, but transthoracic echocardiography has limited sensitivity for the descending aorta.

• A. A V/Q scan evaluates for pulmonary embolism, not aortic dissection.
• C. Exercise testing is contraindicated and irrelevant in suspected acute aortic dissection.
• D. Transthoracic echocardiography has lower sensitivity, particularly for the descending aorta, compared with CT angiography.
• E. A plain chest radiograph may show a widened mediastinum but lacks the sensitivity and specificity to confirm or exclude dissection.

This is a Stanford type A dissection because it involves the ascending aorta, regardless of distal extension. Type A dissections carry a high risk of complications such as aortic rupture, cardiac tamponade, and acute aortic regurgitation, and require emergency surgical repair even in hemodynamically stable patients. Type B dissections (confined to the descending aorta, distal to the left subclavian artery) are generally managed medically with blood pressure and heart rate control unless complicated by malperfusion, rupture, or refractory pain, in which case TEVAR is used.

• A. TEVAR targets the descending aorta and does not address the ascending involvement that defines this as a surgical emergency.
• B. Observation is inappropriate given the high short-term mortality of untreated type A dissection.
• C. Thrombolytics and anticoagulation are contraindicated in aortic dissection as they would worsen bleeding into the false lumen.
• D. Medical therapy alone is the strategy for uncomplicated type B dissection, not for a type A dissection, which requires surgery regardless of hemodynamic stability.

An ankle-brachial index (ABI) between 0.41 and 0.90 indicates peripheral arterial disease, with 0.70-0.90 classified as mild and 0.40-0.69 classified as moderate disease; values of 0.55 and 0.60 fall into the moderate range bilaterally. This is consistent with his classic history of intermittent claudication and diminished pulses. A normal ABI is 1.00-1.40; values above 1.40 suggest non-compressible, calcified vessels (common in diabetes) giving falsely elevated readings, which is not the case here since both values are low.

• B. Falsely elevated ABI from calcification produces values above 1.40, not low values like these.
• C. Values of 0.55 and 0.60 fall in the moderate, not mild, range, and symptomatic PAD warrants further vascular workup.
• D. A normal ABI is between 1.00 and 1.40; these values are well below that range.
• E. Venous insufficiency does not lower the ABI and does not explain exertional calf pain relieved by rest.

This presentation (sudden pain, pallor, coolness, absent pulses, and sensory loss in a patient with atrial fibrillation, a common embolic source) indicates acute limb ischemia, a surgical emergency. Although motor function is still present, suggesting the limb is still salvageable, any sensory deficit signals a threatened limb that requires immediate vascular surgery consultation for urgent revascularization (embolectomy, thrombolysis, or bypass) to prevent progression to irreversible ischemia and limb loss. Delays of even a few hours worsen outcomes, so elective investigation or oral anticoagulation alone are inadequate.

• A. The clinical picture is arterial, not venous, occlusion; compression stockings are inappropriate and potentially harmful.
• B. This presentation represents a limb-threatening emergency, not a benign finding that can be discharged home.
• C. Any delay in a threatened limb with sensory loss risks progression to irreversible ischemia; imaging should not delay surgical consultation.
• D. Oral anticoagulation alone does not address the acute arterial occlusion and outpatient follow-up in a week risks limb loss.

The combination of pleuritic, positional chest pain, a pericardial friction rub, and diffuse ST elevation with PR depression following a viral prodrome is characteristic of acute pericarditis, most often viral or idiopathic in this age group. Unlike myocardial infarction, the ST elevation in pericarditis is diffuse (not localized to a coronary territory) and lacks reciprocal ST depression, and the pain is pleuritic and positional rather than typically exertional or pressure-like. The friction rub, a pathognomonic finding of pericardial inflammation, is not heard in the other listed conditions.

• A. STEMI produces localized ST elevation with reciprocal changes in a coronary distribution, not diffuse ST elevation with PR depression, and pain is typically not positional.
• C. Pulmonary embolism does not cause a friction rub or diffuse ST elevation with PR depression, and classically shows sinus tachycardia or right heart strain pattern on ECG.
• D. Costochondritis causes reproducible chest wall tenderness without fever, friction rub, or ECG changes.
• E. Pneumothorax causes sudden dyspnea with decreased breath sounds and hyperresonance, not a friction rub or diffuse ST changes.

This patient has cardiac tamponade (hypotension, elevated JVP, pulsus paradoxus >10 mm Hg, echocardiographic RV collapse), which is a hemodynamic emergency caused by fluid accumulation restricting diastolic filling. Emergency pericardiocentesis to drain the effusion is the definitive next step to relieve pressure and restore cardiac output. Fluids can be given as a temporizing measure while preparing for drainage but do not treat the underlying problem. Diuretics would worsen filling pressures and are contraindicated in tamponade.

• A. Corticosteroids have no role in acute tamponade management regardless of malignant etiology.
• C. Diuresis reduces preload and can precipitate cardiovascular collapse in tamponade.
• D. Surgical pericardiectomy is reserved for constrictive pericarditis, not acute tamponade.
• E. Fluids may temporarily support pressure but do not relieve the pericardial compression causing instability.

Constrictive pericarditis presents with signs of venous congestion (elevated JVP with Kussmaul sign), a pericardial knock, and marked respiratory variation in mitral inflow (>25%) due to dissociation of intrathoracic and intracardiac pressures from the rigid pericardium. A history of mediastinal radiation is a classic risk factor, and imaging showing pericardial thickening or calcification with normal myocardial wall thickness supports this diagnosis over restrictive cardiomyopathy, where the pericardium is normal and respiratory variation is typically less than 15%. Distinguishing the two is important because constrictive pericarditis can be cured surgically with pericardiectomy.

• A. Dilated cardiomyopathy presents with systolic dysfunction and ventricular dilation, not preserved systolic function with pericardial thickening.
• B. RV infarction causes acute right-sided failure without chronic pericardial thickening or a knock.
• C. Restrictive cardiomyopathy typically shows increased myocardial wall thickness or infiltration and less respiratory variation in mitral inflow.
• D. Tricuspid stenosis produces a diastolic murmur and does not explain the pericardial findings or respiratory variation pattern described.

Myocarditis should be suspected in a young patient with a recent viral prodrome, elevated troponin, new ECG changes, and signs of ventricular dysfunction (S3 gallop) in the absence of coronary artery disease on angiography. Viral myocarditis, most commonly due to enteroviruses or parvovirus B19, causes direct myocardial injury and inflammation leading to troponin release. Cardiac MRI or biopsy can confirm the diagnosis, but the clinical picture with normal coronaries strongly supports this over an ischemic cause. Supportive care and avoidance of strenuous exercise are mainstays of management.

• A. Takotsubo cardiomyopathy is typically triggered by acute emotional or physical stress in older patients, often postmenopausal women, not a viral prodrome.
• B. Pericarditis typically causes diffuse ST elevation and PR depression with pleuritic pain, not isolated troponin rise with an S3 gallop.
• D. STEMI requires ST elevation on ECG and would show a culprit lesion on angiography, which is absent here.
• E. Costochondritis causes reproducible chest wall tenderness without troponin elevation or ECG changes.

Hypertrophic cardiomyopathy (HCM) is the leading cause of sudden cardiac death in young athletes, typically due to ventricular arrhythmias arising from the disorganized myocardial architecture (myocyte disarray) and hypertrophied septum. A family history of sudden death and asymmetric septal hypertrophy with wall thickness ≥15 mm on autopsy or imaging are classic findings. The disorganized myocardial fibers predispose to re-entrant ventricular tachycardia or fibrillation, particularly during intense exertion. Family members should be offered genetic counselling and screening given the autosomal dominant inheritance pattern.

• A. Commotio cordis requires a precordial impact timed with the cardiac cycle, which is not described here.
• B. Anomalous coronary origin causes ischemia from vessel compression but does not produce the described hypertrophy and disarray.
• C. Myocardial bridging can cause ischemia but does not explain the septal hypertrophy and myocyte disarray found at autopsy.
• D. Marfan syndrome causes aortic root dilation and dissection, not septal hypertrophy with myocyte disarray.

This patient has massive (high-risk) PE with persistent hypotension despite fluid resuscitation, confirming obstructive shock from right ventricular failure. Systemic thrombolysis with a fibrinolytic agent such as alteplase is indicated in hemodynamically unstable PE without absolute contraindications, as it rapidly reduces clot burden and RV strain, improving survival. Anticoagulation alone with heparin does not dissolve existing clot quickly enough to reverse hemodynamic collapse. Surgical or catheter-directed embolectomy is reserved for patients with contraindications to thrombolysis or when thrombolysis fails.

• A. An IVC filter prevents further embolization but does nothing to treat the existing massive clot burden causing shock.
• C. Surgical embolectomy is reserved for patients with contraindications to thrombolysis or when thrombolysis fails, not as first-line therapy.
• D. Heparin alone prevents further clot propagation but does not rapidly lyse the existing obstructive clot in shock.
• E. LMWH has a slower onset and is not preferred in the setting of hemodynamic instability requiring rapid clot reduction.

Acutely ill hospitalized medical patients with reduced mobility and at least one additional risk factor for VTE (such as age over 60 or acute infection) should receive pharmacologic thromboprophylaxis with low-molecular-weight heparin unless contraindicated. Mechanical methods such as compression stockings or intermittent pneumatic compression are reserved for patients with a high bleeding risk or as an adjunct, not as first-line monotherapy when pharmacologic prophylaxis is safe to give. Aspirin is not recommended as primary VTE prophylaxis in medical inpatients. This patient has no contraindication to anticoagulation, so pharmacologic prophylaxis is indicated.

• A. Aspirin has not been shown to be adequate VTE prophylaxis in acutely ill medical inpatients.
• B. Mechanical prophylaxis alone is reserved for patients with contraindications to anticoagulation, not first-line therapy here.
• C. Ambulation alone is insufficient in a patient with ongoing illness and expected prolonged immobility.
• D. Mechanical prophylaxis alone is less effective than pharmacologic prophylaxis when anticoagulation is not contraindicated.

An increase in FEV1 of at least 12% and 200 mL from baseline after bronchodilator administration is defined as a significant bronchodilator response. This patient's FEV1 improved from 68% to 82% predicted, an absolute increase well above the 12% threshold, in the setting of an obstructive pattern (reduced FEV1/FVC ratio) and a clinical history of episodic symptoms. This pattern of reversible airflow obstruction is characteristic of asthma rather than COPD, in which obstruction is largely fixed. Demonstrating reversibility supports the diagnosis and distinguishes asthma from other causes of obstruction.

• A. The reduced FEV1/FVC ratio indicates an obstructive, not restrictive, pattern.
• B. The low FEV1/FVC ratio before bronchodilator indicates obstruction, not normal spirometry.
• C. Vocal cord dysfunction does not produce this pattern of reversible obstruction on spirometry.
• E. COPD classically shows little or no reversibility after bronchodilator, unlike this case.

Current Canadian Thoracic Society and GINA-aligned guidelines recommend that patients with mild, infrequent asthma symptoms (such as needing reliever therapy more than twice a week but not daily) use an as-needed low-dose inhaled corticosteroid-formoterol combination rather than a short-acting beta-agonist alone. This approach reduces the risk of severe exacerbations compared with SABA-only reliever therapy, because formoterol has a rapid onset of action and the inhaled corticosteroid component addresses underlying airway inflammation with each use. Scheduled daily controller therapy with a separate inhaler is an alternative but is no longer the preferred first step for this symptom frequency. SABA-only reliever use is discouraged even for mild, infrequent symptoms.

• A. Continuing SABA-only therapy without an inhaled corticosteroid component increases the risk of exacerbations and is no longer recommended.
• C. Leukotriene receptor antagonists are less effective than inhaled corticosteroid-based therapy and are not preferred first-line treatment.
• D. Long-acting muscarinic antagonists are not first-line monotherapy for mild asthma; they are add-on therapy in more severe, uncontrolled disease.
• E. High-dose inhaled corticosteroid with a long-acting beta-agonist is reserved for more severe, poorly controlled asthma, not this patient's mild symptom pattern.

In a moderate-to-severe acute asthma exacerbation, systemic corticosteroids should be given early, after initial bronchodilator therapy, because they reduce airway inflammation and shorten the duration and severity of the exacerbation, as well as reduce the risk of relapse. This patient has already received oxygen and combination bronchodilator therapy (salbutamol and ipratropium) with only partial response, so the next step is systemic corticosteroids, typically oral or intravenous depending on severity and ability to tolerate oral intake. Intravenous magnesium sulfate may be considered as an adjunct in severe cases unresponsive to initial therapy, but it does not replace corticosteroids and is not used alone. Intubation is reserved for impending respiratory failure, which is not yet present here.

• A. This patient has a severe exacerbation with hypoxemia and tachypnea and requires ongoing ED management, not discharge.
• C. Long-acting beta-agonists are not used for acute exacerbations and are not appropriate as monotherapy in this setting.
• D. Intubation is reserved for impending respiratory failure; this patient does not yet show signs of that and has had only partial treatment.
• E. Magnesium sulfate is an adjunct in severe refractory cases, not a substitute for corticosteroids, and should not be used alone.

A post-bronchodilator FEV1/FVC ratio below 0.70 in a patient with a significant smoking history and chronic respiratory symptoms confirms the diagnosis of chronic obstructive pulmonary disease, per GOLD criteria. The severity of airflow limitation is then staged using the post-bronchodilator FEV1 percent predicted; an FEV1 of 58% predicted corresponds to GOLD grade 2 (moderate) obstruction. Because the ratio is measured after bronchodilator, this reflects fixed, largely irreversible airflow obstruction rather than the variable obstruction seen in asthma. The clinical history of chronic productive cough and progressive dyspnea in a long-term smoker further supports COPD over other diagnoses.

• A. The obstruction is measured post-bronchodilator and remains significantly reduced, indicating fixed rather than reversible obstruction typical of asthma.
• B. A reduced FEV1/FVC ratio indicates obstruction, not restriction; restriction would show a preserved or increased ratio with reduced FVC.
• C. The post-bronchodilator ratio below 0.70 with this clinical picture is diagnostic of COPD; further bronchoprovocation testing is not needed.
• D. This degree of airflow obstruction with a smoking history and symptoms is pathological, not a normal aging change.

This patient has an acute COPD exacerbation meeting the classic triad of increased dyspnea, increased sputum volume, and increased sputum purulence, which is the accepted indication for antibiotic therapy in COPD exacerbations. In addition to bronchodilators, a short course of systemic corticosteroids is recommended for most COPD exacerbations because it shortens recovery time and reduces the risk of relapse, while empiric antibiotics targeting likely bacterial pathogens are added when at least two of the three cardinal symptoms are present, including increased sputum purulence. Using both agents together, rather than either alone, reflects guideline-based combined management of a moderate exacerbation.

• A. There are no features suggesting tuberculosis, and empiric antituberculous therapy is not indicated without supporting clinical or microbiologic evidence.
• B. There is no indication of fungal infection here; antifungal therapy is not appropriate.
• C. Antibiotics alone would omit corticosteroids, which are recommended for most exacerbations to reduce recovery time and relapse.
• E. Corticosteroids alone would miss treating the likely bacterial component suggested by purulent sputum, which meets criteria for antibiotics.

This patient's CURB-65 score is calculated from confusion (absent), urea above 7 mmol/L (present), respiratory rate of 30/min or more (present), blood pressure below 90/60 mmHg systolic or diastolic (present, diastolic 58 mmHg), and age 65 years or older (present), giving a score of 4. A CURB-65 score of 3 or higher indicates severe community-acquired pneumonia with a high risk of mortality and warrants hospital admission, with scores of 4 to 5 often prompting consideration of ICU-level care if the patient is hemodynamically unstable or in respiratory failure. This patient is tachypneic and hypotensive but not yet in frank respiratory failure or shock requiring immediate ICU admission, so inpatient admission for intravenous antibiotics and close monitoring is the most appropriate immediate step. Antibiotics should not be delayed for culture results, as early empiric therapy improves outcomes in severe pneumonia.

• A. Direct ICU admission for mechanical ventilation is premature without evidence of respiratory failure or refractory shock; ward admission with close monitoring is appropriate first.
• C. A CURB-65 score of 4 indicates severe pneumonia with significant mortality risk, which is not appropriate for outpatient management.
• D. Empiric antibiotics should be started promptly in severe pneumonia and should not be delayed pending culture results.
• E. A single-dose intramuscular antibiotic as outpatient therapy is inadequate for a patient with a high-risk CURB-65 score.

For previously healthy outpatients with community-acquired pneumonia and no comorbidities or recent antibiotic use, Canadian and international guidelines recommend a high-dose amoxicillin as first-line therapy to cover Streptococcus pneumoniae, the most common pathogen. Macrolide or doxycycline monotherapy is reserved as an alternative if atypical coverage is strongly suspected or amoxicillin is not tolerated, while combination or broader-spectrum regimens are reserved for patients with comorbidities or risk factors for resistant organisms. This patient has none of those risk factors, so narrow-spectrum therapy is preferred to limit resistance and side effects. Outpatient management is appropriate given his stable vital signs and oxygenation.

• A. This combination is appropriate for hospitalized patients with pneumonia, not for outpatient treatment of an uncomplicated case.
• B. Trimethoprim-sulfamethoxazole does not reliably cover Streptococcus pneumoniae and is not a standard choice for CAP.
• C. This intravenous broad-spectrum regimen is reserved for severe hospital-acquired or healthcare-associated infections, not a stable outpatient.
• D. Vancomycin is not absorbed orally for systemic infections and is not first-line for typical community-acquired pneumonia.

Active tuberculosis is a reportable communicable disease in every Canadian province and territory, and physicians are legally obligated to notify public health authorities promptly upon diagnosis, regardless of patient consent. Public health follow-up enables contact tracing, directly observed therapy coordination, and monitoring for treatment completion, which are essential to prevent transmission and the emergence of drug resistance. This reporting duty overrides usual confidentiality norms because of the risk to public health. Mental health legislation is not relevant to TB management, and employer notification would breach confidentiality without legal justification.

• A. Mental health legislation applies to psychiatric emergencies, not to isolation or treatment of infectious tuberculosis.
• B. Genetic testing is irrelevant to an infectious disease and is not part of the public health response to active TB.
• D. Consent is not required for mandatory public health reporting, which is a legal duty independent of patient agreement.
• E. Disclosing the diagnosis to an employer without the patient's consent breaches confidentiality and is not required by law.

Silicosis occurs after prolonged inhalation of crystalline silica dust, classically from occupations such as sandblasting, mining, and stone cutting. The characteristic HRCT findings include small rounded upper-lobe-predominant nodular opacities and eggshell calcification of the hilar and mediastinal lymph nodes, which is a highly specific finding for silica exposure. The restrictive pattern on pulmonary function testing reflects the fibrotic changes caused by chronic silica-induced inflammation. Asbestosis typically produces lower-lobe-predominant fibrosis with pleural plaques rather than eggshell calcification, and the occupational history here points specifically to silica rather than asbestos exposure.

• A. Hypersensitivity pneumonitis is linked to organic antigen exposure and typically shows ground-glass opacities or air trapping, not eggshell calcification.
• B. Asbestosis causes lower-lobe-predominant fibrosis and pleural plaques, not eggshell lymph node calcification, and is linked to asbestos rather than sandblasting.
• C. Sarcoidosis can cause hilar lymphadenopathy but does not produce eggshell calcification as its classic finding, and lacks the specific occupational link described.
• E. Idiopathic pulmonary fibrosis shows lower-lobe-predominant honeycombing without occupational exposure or eggshell calcification.

Light's criteria classify a pleural effusion as an exudate if any one of three conditions is met: pleural fluid to serum protein ratio greater than 0.5, pleural fluid to serum LDH ratio greater than 0.6, or pleural fluid LDH greater than two-thirds the upper limit of normal for serum LDH. Here the protein ratio is 0.6 (42/70) and the LDH ratio is 1.45 (320/220), both exceeding exudate thresholds, and the pleural fluid LDH of 320 U/L is well above two-thirds of 200 U/L (133 U/L). Meeting even one criterion is sufficient to classify the fluid as an exudate, prompting further investigation for causes such as infection, malignancy, or inflammatory disease. Absolute pleural fluid protein level alone is not part of Light's criteria.

• A. This effusion already meets multiple Light's criteria for exudate, so cholesterol measurement is unnecessary to classify it.
• B. The LDH ratio here is 1.45, which exceeds 0.6 and indicates an exudate, not a transudate.
• D. Light's criteria use ratios and the relation to upper limit of normal serum LDH, not an absolute pleural fluid protein cutoff.
• E. The protein ratio here is 0.6, which exceeds 0.5 and indicates an exudate, not a transudate.

Overnight polysomnography is the gold-standard diagnostic test for obstructive sleep apnea, as it measures the apnea-hypopnea index along with sleep staging, oxygen desaturation, and respiratory effort, allowing both diagnosis and severity classification. This patient's history of loud snoring, witnessed apneic episodes, obesity, and dangerous daytime somnolence with a fall-asleep driving event strongly suggests OSA and warrants definitive testing, particularly given the road safety implications. Home sleep apnea testing can be considered in select uncomplicated cases, but polysomnography remains the reference standard, especially when comorbidities or atypical features are present. Pulse oximetry alone lacks the sensitivity and specificity to reliably diagnose or exclude OSA.

• A. Pulmonary function testing assesses airflow obstruction or restriction in lung disease and does not diagnose sleep-disordered breathing.
• B. Arterial blood gas may show chronic hypercapnia in severe cases but does not establish the diagnosis of obstructive sleep apnea.
• C. Pulse oximetry alone lacks the sensitivity and detail needed to reliably diagnose obstructive sleep apnea compared to polysomnography.
• D. Echocardiography can detect pulmonary hypertension as a complication of OSA but does not diagnose the sleep disorder itself.